Target intelligence / Profile preview

Lower esophageal sphincter (LES)

Target
LES
Molecular classification
Other (anatomical/functional muscle structure; not a molecular target such as a receptor, enzyme, or transporter)
01

Overview

The **lower esophageal sphincter** is a specialized region of involuntary smooth muscle located at the junction between the esophagus and stomach. Its primary function is to act as a barrier that prevents gastric contents from refluxing into the esophagus. The LES remains closed except during swallowing, when it relaxes briefly to allow food and liquids to pass into the stomach. Dysfunction or weakness in this sphincter is associated with conditions such as gastroesophageal reflux disease (GERD), achalasia, and hiatal hernia[1][3][5]. The LES is sometimes referred to by alternative names including "gastroesophageal sphincter," "gastroesophageal junction," or "cardiac sphincter" due to its anatomical location near the heart[1][3]. It is classified anatomically rather than molecularly—unlike receptors or enzymes—and thus does not fit standard definitions for therapeutic drug targets like proteins or genes. **Note:** The lower esophageal sphincter is an anatomical structure composed of smooth muscle fibers rather than a discrete molecule/receptor/protein. It does not meet criteria for typical drug targets used in pharmacology databases; therefore, it should be flagged as an incorrect entry if searching for canonical molecular targets[1][3][8].

Other names
Gastroesophageal sphincterGastroesophageal junctionCardiac sphincter
02

Mechanism of action

Not applicable; drugs do not directly target the LES as a molecular entity but may influence its tone or the consequences of its dysfunction.

03

Biological functions

Prevents gastroesophageal refluxRegulates passage of food from esophagus to stomach
04

Disease associations

Gastroesophageal reflux disease (GERD)AchalasiaHiatal hernia
05

Safety considerations

Weakness or dysfunction can lead to GERD and related complications[1][3][5].
06

Interacting drugs

Proton pump inhibitors (indirectly affect LES function by reducing acid)

1 more in the full profile.

Beyond the preview

Go deeper on Lower esophageal sphincter (LES).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lower esophageal sphincter (LES).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call